Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims are supported by the provided label excerpts (inactive ingredients/pH adjusters, subcutaneous use, and mechanism). However, key prescribing information elements are either unsupported or absent from the provided label sections (indications for DVT/PE, dosing frequency, adverse reaction specifics beyond hemorrhage, manufacturer identity, and dosage determination).
Category Scores
Accurate Statements
Fondaparinux sodium injection contains inactive ingredients including water for injection, hydrochloric acid, and sodium hydroxide.
11 DESCRIPTION (states isotonic sodium chloride solution and may contain sodium hydroxide and/or hydrochloric acid as pH adjusters; includes water for injection in the formulation description).
Fondaparinux sodium injection works by inhibiting a specific clotting factor in the blood, thereby reducing the risk of clot formation.
12.1 Mechanism of Action (selective inhibition of Factor Xa via ATIII; interrupts coagulation cascade and inhibits thrombin formation and thrombus development).
Fondaparinux sodium injection is administered subcutaneously (under the skin).
11 DESCRIPTION (ARIXTRA supplied as ... injectable solution for subcutaneous use).
Unsupported Statements
Fondaparinux sodium injection is used to prevent and treat blood clots.
The provided label excerpts do not include specific indications text; only mechanism-related content is available under Indications/Usage. Therefore prevention/treatment language is not supported by the provided sections.
Fondaparinux sodium injection is prescribed for deep vein thrombosis (DVT) and pulmonary embolism (PE).
The provided label excerpts do not include DVT/PE indication statements.
Fondaparinux sodium injection is typically given once daily.
The provided label excerpts do not include dosing frequency information.
Common side effects of fondaparinux sodium injection include bleeding, anemia, and nausea.
The provided adverse reactions excerpt explicitly lists hemorrhage (and other clinically significant reactions elsewhere), but anemia and nausea are not shown in the provided sections.
The primary manufacturer of fondaparinux sodium injection is Aspen Pharmacare Holdings Limited.
No manufacturer information is present in the provided label excerpts.
Dosage for fondaparinux sodium injection is determined by a healthcare professional and is typically based on the patient's weight and the specific medical condition being treated.
The provided label excerpts do not include dosage guidance or statements about weight/condition-based dosing or who determines dosing.
Contradictions
Important Omissions
Indications and usage specifics (e.g., exact labeled indications, prevention vs treatment wording) are not provided/validated against the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple dosing/usage-related claims are unsupported by the provided label excerpts (indications and dosing frequency), and adverse reaction content is incomplete/partially inaccurate (anemia and nausea not supported in the excerpt). Without supported dosing/indication text, the response could mislead about appropriate use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several claims (DVT/PE indications, once-daily dosing, and specific adverse reactions/anemia/nausea, plus manufacturer and dosage-determination basis) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to label-supported content from the provided excerpts (formulation pH adjusters, subcutaneous route, and Factor Xa/ATIII mechanism). Omit or revise claims about labeled indications, dosing frequency, specific side-effect lists beyond hemorrhage, manufacturer identity, and weight/condition-based dosing unless those exact sections are available in the label material.